By NextBestFitDrug and device makers
Manufacturers whose products a payer can cover, price, or decline.
Under your mix of paths
Using your saved plan. 0 paths picked.Edit all picks
Problems that hurt them
Paths that fix these help them.
- Slower access to new drugs and technology: Lower prices reduce research returns for biotech workers and investors.
- Central coverage decisions can feel like rationing: A declined product loses the whole national market.
Problems they gain from
Paths that fix these cost them.
- Pharmacy benefit managers profit from opaque drug pricing: Rebates buy formulary placement for their products.
- U.S. prices are far higher than in other countries: U.S. prices are well above those in peer countries.
- Brand-name drug prices far above production cost: Market exclusivity supports high prices and shareholder returns.
- Patent thickets and evergreening delay generics: Secondary patents extend brand manufacturers’ monopolies.
- R&D is funded by high prices, which ties innovation to unaffordability: High prices fund research and support expected investor returns.
- Low-value care and overtreatment: They sell devices and tests used in low-value care.